Abstract
Background: We aimed to clarify the impact of the donor source of allogeneic stem cell transplantation (allo-SCT) on Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(-) ALL] with focus on cord blood (CB). Patients and methods: We retrospectively analyzed data of 1726 patients who underwent myeloablative allo-SCT for adult Ph(-) ALL. The sources of the allo-SCT were related donors (RD; N = 684), unrelated donors (URD; N = 809), and CB (N = 233). Results: Overall survival (OS) in patients after CB allo-SCT in first complete remission (CR1) was comparable with that after RD or URD allo-SCT (RD: 65%, URD: 64% and CB: 57% at 4 years, P = 0.11). CB was not a significant risk factor for relapse or non-relapse mortality as well as for OS in multivariate analyses. Similarly, the donor source was not a significant risk factor for OS in subsequent CR or non-CR (RD: 47%, URD: 39% and CB: 48% in subsequent CR, P = 0.33; RD: 15%, URD: 21% and CB: 18% in non-CR, P = 0.20 at 4 years). Conclusion: Allo-SCT using CB led to OS similar to those of RD or URD in any disease status. To avoid missing the appropriate timing, CB is a favorable alternative source for adult Ph(-) ALL patients without a suitable RD or URD.
| Original language | English |
|---|---|
| Pages (from-to) | 1594-1602 |
| Number of pages | 9 |
| Journal | Annals of Oncology |
| Volume | 24 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2013 Jun |
Fingerprint
Keywords
- Allogeneic stem cell transplantation
- Cord blood
- Donor source
- Philadelphia chromosome-negative acute lymphoblastic leukemia
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Impact of a donor source on adult philadelphia chromosome-negative acute lymphoblastic leukemia : A retrospective analysis from the adult acute lymphoblastic leukemia working group of the japan society for hematopoietic cell transplantation. / Nishiwaki, S.; Miyamura, K.; Ohashi, K.; Kurokawa, M.; Taniguchi, S.; Fukuda, T.; Ikegame, K.; Takahashi, S.; Mori, Takehiko; Imai, K.; Iida, H.; Hidaka, M.; Sakamaki, H.; Morishima, Y.; Kato, K.; Suzuki, R.; Tanaka, J.
In: Annals of Oncology, Vol. 24, No. 6, 06.2013, p. 1594-1602.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of a donor source on adult philadelphia chromosome-negative acute lymphoblastic leukemia
T2 - A retrospective analysis from the adult acute lymphoblastic leukemia working group of the japan society for hematopoietic cell transplantation
AU - Nishiwaki, S.
AU - Miyamura, K.
AU - Ohashi, K.
AU - Kurokawa, M.
AU - Taniguchi, S.
AU - Fukuda, T.
AU - Ikegame, K.
AU - Takahashi, S.
AU - Mori, Takehiko
AU - Imai, K.
AU - Iida, H.
AU - Hidaka, M.
AU - Sakamaki, H.
AU - Morishima, Y.
AU - Kato, K.
AU - Suzuki, R.
AU - Tanaka, J.
PY - 2013/6
Y1 - 2013/6
N2 - Background: We aimed to clarify the impact of the donor source of allogeneic stem cell transplantation (allo-SCT) on Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(-) ALL] with focus on cord blood (CB). Patients and methods: We retrospectively analyzed data of 1726 patients who underwent myeloablative allo-SCT for adult Ph(-) ALL. The sources of the allo-SCT were related donors (RD; N = 684), unrelated donors (URD; N = 809), and CB (N = 233). Results: Overall survival (OS) in patients after CB allo-SCT in first complete remission (CR1) was comparable with that after RD or URD allo-SCT (RD: 65%, URD: 64% and CB: 57% at 4 years, P = 0.11). CB was not a significant risk factor for relapse or non-relapse mortality as well as for OS in multivariate analyses. Similarly, the donor source was not a significant risk factor for OS in subsequent CR or non-CR (RD: 47%, URD: 39% and CB: 48% in subsequent CR, P = 0.33; RD: 15%, URD: 21% and CB: 18% in non-CR, P = 0.20 at 4 years). Conclusion: Allo-SCT using CB led to OS similar to those of RD or URD in any disease status. To avoid missing the appropriate timing, CB is a favorable alternative source for adult Ph(-) ALL patients without a suitable RD or URD.
AB - Background: We aimed to clarify the impact of the donor source of allogeneic stem cell transplantation (allo-SCT) on Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(-) ALL] with focus on cord blood (CB). Patients and methods: We retrospectively analyzed data of 1726 patients who underwent myeloablative allo-SCT for adult Ph(-) ALL. The sources of the allo-SCT were related donors (RD; N = 684), unrelated donors (URD; N = 809), and CB (N = 233). Results: Overall survival (OS) in patients after CB allo-SCT in first complete remission (CR1) was comparable with that after RD or URD allo-SCT (RD: 65%, URD: 64% and CB: 57% at 4 years, P = 0.11). CB was not a significant risk factor for relapse or non-relapse mortality as well as for OS in multivariate analyses. Similarly, the donor source was not a significant risk factor for OS in subsequent CR or non-CR (RD: 47%, URD: 39% and CB: 48% in subsequent CR, P = 0.33; RD: 15%, URD: 21% and CB: 18% in non-CR, P = 0.20 at 4 years). Conclusion: Allo-SCT using CB led to OS similar to those of RD or URD in any disease status. To avoid missing the appropriate timing, CB is a favorable alternative source for adult Ph(-) ALL patients without a suitable RD or URD.
KW - Allogeneic stem cell transplantation
KW - Cord blood
KW - Donor source
KW - Philadelphia chromosome-negative acute lymphoblastic leukemia
UR - http://www.scopus.com/inward/record.url?scp=84878438842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878438842&partnerID=8YFLogxK
U2 - 10.1093/annonc/mds655
DO - 10.1093/annonc/mds655
M3 - Article
VL - 24
SP - 1594
EP - 1602
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 6
ER -